SCHEMBL18482197

SCHEMBL18482197

COC(CO)C(O)[C@](F)(Cl)n1ccc(N)nc1=O

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 3/20 0.36
SLC22A6 Q4U2R8 1/20 0.35
PDE3A Q14432 3/20 0.34
PDE4D Q08499 1/20 0.34
SLC29A1 Q99808 1/20 0.34
LMNA P02545 3/20 0.33
THRB P10828 1/20 0.33
MTOR P42345 1/20 0.33
MDM2 Q00987 1/20 0.33
NCOA1 Q15788 1/20 0.33
NCOA3 Q9Y6Q9 1/20 0.33
NT5E P21589 1/20 0.30
CACNA1F O60840 2/20 0.30
ALB P02768 2/20 0.30
MAPT P10636 2/20 0.30
CACNA1D Q01668 2/20 0.30
CACNA1S Q13698 2/20 0.30
CACNA1C Q13936 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23950133 0.88 FGFR1 (0.37) FGFR1SLC22A6PDE3APDE4DSLC29A1
SCHEMBL22847460 0.88 FGFR1 (0.37) FGFR1SLC22A6PDE3APDE4DSLC29A1
SCHEMBL16330681 0.83 FGFR1 (0.37) FGFR1SLC22A6PDE3APDE4DSLC29A1
SCHEMBL22847449 0.82 FGFR1 (0.38) FGFR1SLC22A6PDE3APDE4DSLC29A1
SCHEMBL19987342 0.81 FGFR1 (0.38) FGFR1SLC22A6PDE3APDE4DSLC29A1
SCHEMBL16426709 0.79 FGFR1 (0.43) FGFR1SLC22A6PDE3APDE4DSLC29A1
SCHEMBL22765438 0.78 FGFR1 (0.35) FGFR1SLC22A6PDE3APDE4DSLC29A1
SCHEMBL20669062 0.78 FGFR1 (0.35) FGFR1SLC22A6PDE3APDE4DSLC29A1
SCHEMBL18324635 0.78 FGFR1 (0.35) FGFR1SLC22A6PDE3APDE4DSLC29A1
SCHEMBL19245259 0.76 FGFR1 (0.34) FGFR1SLC22A6PDE3APDE4DSLC29A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170037078-A1 2' -DISUBSTITUTED NUCLEOSIDE ANALOGS FOR TREATMENT OF THE FLAVIVIRIDAE FAMILY OF VIRUSES AND CANCER COCRYSTAL PHARMA, INC. (US) 2017-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170037078-A1 2' -DISUBSTITUTED NUCLEOSIDE ANALOGS FOR TREATMENT OF THE FLAVIVIRIDAE FAMILY OF VIRUSES AND CANCER HAVCR2, HCCS, NAMPT FGFR1 732/4885SLC22A6 206/4885PDE3A 2560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.